- Optogenetic induction of alpha-synuclein aggregation in human dopaminergic neurons to model Parkinson's disease pathology.
Optogenetic induction of alpha-synuclein aggregation in human dopaminergic neurons to model Parkinson's disease pathology.
STAR protocols (2023-09-24)
Eun A Ra, Min Seong Kim, Gabsang Lee
PMID37742181
RÉSUMÉ
Alpha-synuclein (α-syn) aggregation is a principal factor in Parkinson's disease (PD) onset. Here, we present a protocol for optogenetic induction of α-syn aggregation in human midbrain dopaminergic (mDA) neurons, facilitating a detailed PD pathology study. We describe steps for nucleofection of the opto-α-syn construct, single colony selection and validation, alongside mDA neuron differentiation and rapid induction of toxic α-syn aggregates via blue light. This establishes a potent human induced pluripotent-stem-cell-based platform for PD drug testing and validation. For complete details on the use and execution of this protocol, please refer to Kim et al. (2023).1.
MATÉRIAUX
Référence du produit
Marque
Description du produit
Sigma-Aldrich
Puromycine dihydrochloride from Streptomyces alboniger, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
N6,2′-O-Dibutyryladénosine 3′,5′-monophosphate cyclique sodium salt, ≥96% (HPLC), powder
Sigma-Aldrich
Anticorps anti-α-synucléine agrégée, clone 5G4, clone 5G4, from mouse, purified by affinity chromatography